Unibest

Pharmaceutical intermediates

Fruquintinib Intermediates

5 pharmaceutical intermediates for Fruquintinib. Indication: Endometrial cancer; Colorectal cancer.

提交项目All intermediates

About Fruquintinib

Originator
Hutchison Medipharma Ltd
Indication
Endometrial cancer; Colorectal cancer
Approved Date
11/08/2023
DS/DP
05/09/2028

Available intermediates

5 intermediates currently listed for Fruquintinib. Request specifications, documentation or a quotation for any item below.

Fruquintinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
6,7-Dimethoxy-3,4-dihydroquinazoline -4-one13794-72-4//
4-Chloro-6,7-dimethoxyquinazoline13790-39-1//
6-methoxy-2-methylbenzofuran -3-carboxylic acid103986-33-0//
6-Hydroxy-2-methylbenzofuran -3-carboxylic acid854515-52-9//
6-Hydroxy-N-methyl-2-methyl-1-benzofuran-3-carboxamide638217-08-0//

Other programs under F

FebuxostatFexuprazan HClFezolinetantFilgotinib MaleateFinerenoneFluralanerFostamatinib disodium hexahydrateFutibatinib

Building toward Fruquintinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →